Jawad H Butt1, Nikolaj Ihlemann2, Ole De Backer2, Lars Søndergaard2, Eva Havers-Borgersen2, Gunnar H Gislason3, Christian Torp-Pedersen4, Lars Køber2, Emil L Fosbøl2. 1. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: jawad_butt91@hotmail.com. 2. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark; Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark; National Institute of Public Health, University of Southern Denmark, Odense, Denmark. 4. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: Patients undergoing surgical aortic valve replacement (SAVR) are considered at high risk of infective endocarditis (IE). However, data on the risk of IE following transcatheter aortic valve replacement (TAVR) are sparse and limited by the lack of long-term follow-up as well as a direct comparison with patients undergoing SAVR. OBJECTIVES: This study sought to investigate the long-term incidence of IE in patients undergoing TAVR and to compare the long-term risk of IE with patients undergoing isolated SAVR. METHODS: In this nationwide observational cohort study, all patients undergoing TAVR and isolated SAVR from January 1, 2008, to December 31, 2016, with no history of IE and alive at discharge were identified using data from Danish nationwide registries. RESULTS: A total of 2,632 patients undergoing TAVR and 3,777 patients undergoing isolated SAVR were identified. During a mean follow-up of 3.6 years, 115 patients (4.4%) with TAVR and 186 patients (4.9%) with SAVR were admitted with IE. The median time from procedure to IE hospitalization was 352 days (25th to 75th percentile: 133 to 778 days) in the TAVR group and 625 days (25th to 75th percentile: 209 to 1,385 days) in the SAVR group. The crude incidence rates of IE were 1.6 (95% confidence interval [CI]: 1.4 to 1.9) and 1.2 (95% CI: 1.0 to 1.4) events per 100 person-years in TAVR and SAVR patients, respectively. The cumulative 1-year risk of IE was 2.3% (95% CI: 1.8% to 2.9%) and 1.8% (95% CI: 1.4% to 2.3%) in TAVR and SAVR patients, respectively. Correspondingly, the cumulative 5-year risk of IE was 5.8% (95% CI: 4.7% to 7.0%) and 5.1% (95% CI: 4.4% to 6.0%), respectively. In multivariable Cox proportional hazard analysis, TAVR was not associated with a statistically significant different risk of IE compared with SAVR (hazard ratio: 1.12; 95% CI: 0.84 to 1.49). CONCLUSIONS: The 5-year incidence of IE following TAVR was 5.8% and not significantly different than the incidence following SAVR.
BACKGROUND:Patients undergoing surgical aortic valve replacement (SAVR) are considered at high risk of infective endocarditis (IE). However, data on the risk of IE following transcatheter aortic valve replacement (TAVR) are sparse and limited by the lack of long-term follow-up as well as a direct comparison with patients undergoing SAVR. OBJECTIVES: This study sought to investigate the long-term incidence of IE in patients undergoing TAVR and to compare the long-term risk of IE with patients undergoing isolated SAVR. METHODS: In this nationwide observational cohort study, all patients undergoing TAVR and isolated SAVR from January 1, 2008, to December 31, 2016, with no history of IE and alive at discharge were identified using data from Danish nationwide registries. RESULTS: A total of 2,632 patients undergoing TAVR and 3,777 patients undergoing isolated SAVR were identified. During a mean follow-up of 3.6 years, 115 patients (4.4%) with TAVR and 186 patients (4.9%) with SAVR were admitted with IE. The median time from procedure to IE hospitalization was 352 days (25th to 75th percentile: 133 to 778 days) in the TAVR group and 625 days (25th to 75th percentile: 209 to 1,385 days) in the SAVR group. The crude incidence rates of IE were 1.6 (95% confidence interval [CI]: 1.4 to 1.9) and 1.2 (95% CI: 1.0 to 1.4) events per 100 person-years in TAVR and SAVR patients, respectively. The cumulative 1-year risk of IE was 2.3% (95% CI: 1.8% to 2.9%) and 1.8% (95% CI: 1.4% to 2.3%) in TAVR and SAVR patients, respectively. Correspondingly, the cumulative 5-year risk of IE was 5.8% (95% CI: 4.7% to 7.0%) and 5.1% (95% CI: 4.4% to 6.0%), respectively. In multivariable Cox proportional hazard analysis, TAVR was not associated with a statistically significant different risk of IE compared with SAVR (hazard ratio: 1.12; 95% CI: 0.84 to 1.49). CONCLUSIONS: The 5-year incidence of IE following TAVR was 5.8% and not significantly different than the incidence following SAVR.
Authors: Vassili Panagides; Mohamed Abdel-Wahab; Norman Mangner; Eric Durand; Nikolaj Ihlemann; Marina Urena; Costanza Pellegrini; Francesco Giannini; Piotr Scislo; Zenon Huczek; Martin Landt; Vincent Auffret; Jan Malte Sinning; Asim N Cheema; Luis Nombela-Franco; Chekrallah Chamandi; Francisco Campelo-Parada; Erika Munoz-Garcia; Howard C Herrmann; Luca Testa; Won-Keun Kim; Helene Eltchaninoff; Lars Søndergaard; Dominique Himbert; Oliver Husser; Azeem Latib; Hervé Le Breton; Clement Servoz; Philippe Gervais; David Del Val; Axel Linke; Lisa Crusius; Holger Thiele; David Holzhey; Josep Rodés-Cabau Journal: Clin Res Cardiol Date: 2022-03-09 Impact factor: 6.138
Authors: Consuelo Fernández-Avilés; Juan C Castillo; Gloria Heredia; Adriana Resúa; Rafael González; Manuel Pan; Manuel Anguita Journal: Cardiol J Date: 2021-11-17 Impact factor: 3.487
Authors: Anthony J Buckley; Richard Tanner; Brian Armstrong; Saber Hassan; Barbara Moran; Jamie Byrne; Susan Groarke; Ronan Margey; Ivan P Casserly Journal: Ir J Med Sci Date: 2022-05-03 Impact factor: 2.089
Authors: Diego H González-Bravo; Sergio Alegre-Boschetti; Richard Silva-Cantillo; Joshua Mercado-Maldonado; Reyshley Ramos-Márquez; Gabriel Torres-Rivera; Carlos Cortés; Josue Mercado-Crespo Journal: Case Rep Cardiol Date: 2021-07-11